Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
88% buy on barchart.com
Good morning guys and gals. Looking forward to a real great day!
Good morning longs. .083 ask.
What will 3.5mm be worth by Christmas?
Nice! Noticed it was recently updated on 2020-11-30. Interesting indeed.
Shorts will pay dearly.
How high can EWLL run?
Astro, what is the connection??
HUGE! A
$BSSP +
$ENZC
connection."
buy out Regen for a minimium of 750 Million dollars.
What does that translate to PPS given such large outstanding shares?
Let it Spike I'm okay with that then Let it retrace a little bit; I'm a good with that too. They can't beat them join them.
Last PR was in May. Probably a pump knowing the handles on this board all of a sudden. Well, so be it, maybe I will break even.
Ok. Have a stash of EWLL. Bar charts Trending~Buy
Why all of a sudden is Ewell supposedly waking up? What is different now?
I hope to sell half of my position at $4 or $5 and let the other half ride.
How long do I need to hold this time?
My position would amount to $97,500,000 @$150/share. "Elizabeth, I'm coming to see you."
I sold Novav~x just before it went up over $100. Made a huge mistake and I'm not going to make the same mistake here. Like the song, "I shall not be moved."
Someone please give me a link to SEC to voice a complaint of coordinated efforts to bring price down.
Either Clays group or Timothy Sykes group. They should be investigated.
Good accumulation .
Patent Info:
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation
PR Newswire - Wed Aug 07, 12:30PM UTC
SAN DIEGO , Aug. 7, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today filing of a US patent application covering a newly discovered synergy between inhibition of NR2F6 and cannabidiol (CBD). The new data demonstrates enhanced ability to reduce cancer growth in an efficacious manner while appearing not to induce any form of toxicity.
In a series of experiments, Regen collaborators extracted immune system cells from mice called 'dendritic cells'. These cells where treated with cannabidiol, which caused suppression of their ability to activate cancer killing immune T cells. Surprisingly, in the presence of NR2F6 inhibition, the cannabidiol actually increased ability to activate T cells. The Company currently possesses small molecule inhibitors of NR2F6, as well as various genetic means such as inducers of RNA Interference, to block expression of NR2F6.
"Numerous studies have shown the NR2F6 is critically involved in the ability of cancer cells to resist death, as well as to possess other pathogenic properties (1-3)," according to Thomas Ichim , PhD, co-inventor of the patent and a senior scientific consultant to Regen BioPharma Inc. "It is very interesting that NR2F6 also acts as an 'immunological checkpoint' in that it prevents immune system activation (4-6). By using small molecules, as well as RNA interference, we are able to de-repress the immune system in cancer models. What is striking about the data disclosed today is that inhibition of NR2F6 not only increases activity of dendritic cells, but also changes cannabidiol from an immune inhibitor to an immune stimulator."
Chairman and CEO David Koos noted, "Checkpoint inhibitors are a new class of drugs, which include Ipilimumab (Yervoy® Bristol Myers Squibb, 2018 estimated sales of $1.5 Billion 1 ), and Pembrolizumab (Keytruda® Merck, 2017 sales of $3.4 Billion 2 ). Current checkpoint inhibitors act to augment immune responses but do not have direct anticancer effects. By creating approaches to inhibit NR2F6, the Company aims to develop a new class of checkpoint inhibitors that concurrently block tumor growth while enhancing the immune system."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com ;.
Disclaimer : This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
David Koos serves as Chairman & CEO of both Regen BioPharma Inc. and Zander Therapeutics Inc. Harry Lander serves as President and Chief Scientific Officer of both Regen BioPharma Inc. and Zander Therapeutics. Zander Therapeutics Inc. is the sole licensee of Regen's intellectual property for veterinary applications.
1. Jin, C., Xiao, L., Zhou, Z., Zhu, Y., Tian, G., and Ren, S. (2019) MiR-142-3p suppresses the proliferation, migration and invasion through inhibition of NR2F6 in lung adenocarcinoma. Hum Cell
2. Niu, C., Sun, X., Zhang, W., Li, H., Xu, L., Li, J., Xu, B., and Zhang, Y. (2016) NR2F6 Expression Correlates with Pelvic Lymph Node Metastasis and Poor Prognosis in Early-Stage Cervical Cancer. Int J Mol Sci 17
3. Li, X. B., Jiao, S., Sun, H., Xue, J., Zhao, W. T., Fan, L., Wu, G. H., and Fang, J. (2011) The orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it regulates survivability of colon cancer cells. Cancer Lett 309 , 137-144
4. Klepsch, V., Gerner, R. R., Klepsch, S., Olson, W. J., Tilg, H., Moschen, A. R., Baier, G., and Hermann-Kleiter, N. (2018) Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis. Gut 67 , 1434-1444
5. Klepsch, V., Hermann-Kleiter, N., Do-Dinh, P., Jakic, B., Offermann, A., Efremova, M., Sopper, S., Rieder, D., Krogsdam, A., Gamerith, G., Perner, S., Tzankov, A., Trajanoski, Z., Wolf, D., and Baier, G. (2018) Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun 9 , 1538
6. Klepsch, V., Hermann-Kleiter, N., and Baier, G. (2016) Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunol Lett 178 , 31-36
1 https://www.fiercepharma.com/special-report/yervoy-bristol-myers-squibb
2 https://www.biospace.com/article/projections-made-for-5-biggest-pharma-products-in-2024/
Contact Information:
Regen BioPharma Inc.
David R. Koos , Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
? View original content: http://www.prnewswire.com/news-releases/regen-biopharma-inc-files-immuno-oncology-patent-application-on-synergy-of-cannabidiol-with-nr2f6-modulation-300897718.html
SOURCE Regen BioPharma Inc.
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
PR Newswire - Thu Oct 03, 12:30PM UTC
Regen BioPharma Inc. (OTCQB:RGBP) and (OTCQB:RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic approach successfully reduces rheumatoid arthritis in an animal model. The data disclosed today, which is the subject of a United States patent application, show that the Company's drug candidate induces activation of a type of immune system cell termed "T Regulatory Cells". The immunology community believes that T regulatory cells serve a fundamental role in protecting the body from uncontrolled inflammation or autoimmunity[1].
"The reduction of rheumatoid arthritis disease, which correlated with an increase in T regulatory cell numbers and a decrease in Th17 cells induced by the cannabidiol-based therapeutic drug mimics natural conditions in which autoimmunity goes into remission," said Thomas Ichim, PhD, Senior Advisor to the Company. "Similar changes in immunological parameters are seen in pregnancy, in which various autoimmune diseases are known to go into remission[2]. We believe that we may have uncovered a new approach to autoimmunity that spares the patients the toxicity and side effects of non-specific immune suppression, which is the current treatment paradigm today."
Autoimmune diseases are conditions in which the immune system starts attacking components of the body. Major autoimmune conditions include rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and lupus.
"These current findings add another therapeutic candidate to our existing portfolio which centers of modulation of inflammatory pathways such as NR2F6," noted David Koos, Chairman and CEO of Regen BioPharma. "What this means to our small molecule drug development programs is CBD appears when used with other compounds to amplify the desired outcome. Our current pipeline of NR2F6 small molecules both augment and inhibit interleukin-17 production, we see potential synergy between today's disclosed data and our ongoing small molecule programs."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB:RGBP) and (OTCQB:RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc. David R. Koos, Ph.D.Chairman & Chief Executive Officer+1-619-702-1404 Phone +1-619-330-2328 Faxhttp://www.regenbiopharma.com david.koos@regenbiopharma.com
[1] Göschl et al. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol. 2019 May;41(3):301-314. https://link.springer.com/article/10.1007%2Fs00281-019-00741-8
[2] https://www.sciencedaily.com/releases/2010/06/100617102406.htm
https://c212.net/c/img/favicon.png?sn=IO92514&sd=2019-10-03
View original content:http://www.prnewswire.com/news-releases/regen-biopharma-successfully-treats-rheumatoid-arthritis-using-cannabidiol-cbd-based-immune-modulatory-treatments-300930351.html
SOURCE Regen BioPharma Inc.
https://rt.prnewswire.com/rt.gif?NewsItemId=IO92514&Transmission_Id=201910030830PR_NEWS_USPR_____IO92514&DateId=20191003
The big question is, Who is likely to win?
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
PR Newswire - Thu Oct 03, 12:30PM UTC
Yes, and Jesus IS King. Good point.
No hostile takeover possibly here. This is the next BigPharma. IMHO
Good point Bonnie Mac
Thanks Love pink for the heads-up
I cherish my Covid19 cure/HIV cure shares and will not part with them until $2. Then will keep half for the future. $$$
Anyone trying to get an order filled at 0012?
.02
Shows Harry's wife Diana owning 50.51% of common shares. Cool.
Ok, thanks.
Armstjo~ haha that would be fantastic. $30/share would give me over $19 million. I hope my heart can handle it.
2,758,670,097 shares out. Will the number of shares that Harry and Charles have be noted in the 8K.
SURE IT'S A HOSTILE TAKEOVER,
I hope that Charles has taken contingency steps to prevent a takeover.
This could very well be a hostile takeover by big farma. Could be a bidding war. It's possible that big farma is already buying up shares.
From this mornings PR~
This Enzolytics anti-HIV treatment is now being advanced through the certification stage to thereafter be made available for patient therapy.
Good, morning longs. .12 on the ask premarket. GLTA
Please stay around Live*Pink. We need your input.
All I can say is YES.